JP2020500178A5 - - Google Patents

Download PDF

Info

Publication number
JP2020500178A5
JP2020500178A5 JP2019523671A JP2019523671A JP2020500178A5 JP 2020500178 A5 JP2020500178 A5 JP 2020500178A5 JP 2019523671 A JP2019523671 A JP 2019523671A JP 2019523671 A JP2019523671 A JP 2019523671A JP 2020500178 A5 JP2020500178 A5 JP 2020500178A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
alkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019523671A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500178A (ja
JP7042468B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/061870 external-priority patent/WO2018093949A1/en
Publication of JP2020500178A publication Critical patent/JP2020500178A/ja
Publication of JP2020500178A5 publication Critical patent/JP2020500178A5/ja
Application granted granted Critical
Publication of JP7042468B2 publication Critical patent/JP7042468B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019523671A 2016-11-16 2017-11-15 Magl阻害剤 Active JP7042468B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423102P 2016-11-16 2016-11-16
US62/423,102 2016-11-16
PCT/US2017/061870 WO2018093949A1 (en) 2016-11-16 2017-11-15 Magl inhibitors

Publications (3)

Publication Number Publication Date
JP2020500178A JP2020500178A (ja) 2020-01-09
JP2020500178A5 true JP2020500178A5 (OSRAM) 2020-12-24
JP7042468B2 JP7042468B2 (ja) 2022-03-28

Family

ID=62145825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019523671A Active JP7042468B2 (ja) 2016-11-16 2017-11-15 Magl阻害剤

Country Status (27)

Country Link
US (2) US11059822B2 (OSRAM)
EP (1) EP3541820B1 (OSRAM)
JP (1) JP7042468B2 (OSRAM)
KR (1) KR20190080935A (OSRAM)
CN (1) CN110267962B (OSRAM)
AU (1) AU2017361253B2 (OSRAM)
BR (1) BR112019009880A2 (OSRAM)
CA (1) CA3043617A1 (OSRAM)
CL (1) CL2019001336A1 (OSRAM)
CO (1) CO2019004945A2 (OSRAM)
CR (1) CR20190239A (OSRAM)
DO (1) DOP2019000118A (OSRAM)
EA (1) EA038150B1 (OSRAM)
EC (1) ECSP19034535A (OSRAM)
ES (1) ES2952582T3 (OSRAM)
IL (1) IL266547B (OSRAM)
JO (1) JOP20190107A1 (OSRAM)
MA (1) MA46855A (OSRAM)
MX (1) MX389627B (OSRAM)
NI (1) NI201900049A (OSRAM)
PE (1) PE20191145A1 (OSRAM)
PH (1) PH12019501079A1 (OSRAM)
RU (1) RU2019115784A (OSRAM)
TN (1) TN2019000149A1 (OSRAM)
UA (1) UA125523C2 (OSRAM)
WO (1) WO2018093949A1 (OSRAM)
ZA (1) ZA201903099B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2861648T3 (es) * 2016-05-12 2021-10-06 Lundbeck La Jolla Research Center Inc Compuestos de espirociclo y procedimientos de fabricación y uso de los mismos
BR112019009992A2 (pt) 2016-11-16 2019-08-27 Abide Therapeutics Inc formulações farmacêuticas
CA3043610A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Crystalline forms of a magl inhibitor
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
ES2940111T3 (es) 2017-05-23 2023-05-03 H Lundbeck As Inhibidores de MAGL de pirazol
CR20200088A (es) 2017-08-29 2020-04-08 Lundbeck La Jolla Research Center Inc Compuestos espirocíclicos y sus métodos de preparación y uso
MA50041A (fr) 2017-08-29 2020-07-08 Lundbeck La Jolla Research Center Inc Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
JP2021531287A (ja) * 2018-07-19 2021-11-18 ファイザー・インク Magl阻害剤としての複素環式スピロ化合物
PE20211089A1 (es) 2018-08-13 2021-06-14 Hoffmann La Roche Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa
BR112021025516A2 (pt) 2020-04-21 2022-11-01 H Lundbeck As Processos para a fabricação de 4-(2-(pirrolidin-1-il)-4-(trifluorometil)benzil)piperazina-1-carboxilato de 1,1,1,3,3,3-hexafluoropropan-2-ila e da forma 2 do sal monocloridrato do mesmo
US11434222B2 (en) 2020-11-13 2022-09-06 H. Lundbeck A/S MAGL inhibitors
MX2024008337A (es) 2021-12-29 2024-07-30 Psy Therapeutics Inc Inhibicion de la monoacilglicerol lipasa (magl).
CN119137114A (zh) 2022-05-04 2024-12-13 H.隆德贝克有限公司 作为单酰基甘油脂肪酶抑制剂的(s)-1-(哒嗪-3-基氨基甲酰基)-6-氮杂螺[2.5]辛烷-6-甲酸1,1,1,3,3,3-六氟丙-2-酯的结晶形式
WO2024168426A1 (en) 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003002A (en) 1910-10-10 1911-09-12 Gustave J Martel Tire-patching device.
MXPA03008109A (es) 2001-03-07 2003-12-12 Pfizer Prod Inc Moduladores de la actividad de receptores de quimiocinas.
US20080255150A1 (en) * 2005-11-05 2008-10-16 Astrazeneca Ab Novel Compounds
WO2008023720A1 (en) 2006-08-23 2008-02-28 Astellas Pharma Inc. Urea compound or salt thereof
CA2716863A1 (en) 2008-03-05 2009-09-11 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
CA2775703C (en) 2009-09-29 2014-07-08 Polyone Corporation Polyester articles having simulated metallic or pearlescent appearance
KR101859409B1 (ko) 2009-10-23 2018-05-18 얀센 파마슈티카 엔.브이. 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로[3,4-c]피롤
WO2011109277A1 (en) 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
PL2800565T3 (pl) 2012-01-06 2020-09-21 Lundbeck La Jolla Research Center, Inc. Związki karbaminianowe i sposoby ich wytwarzania oraz zastosowanie
JP2014005245A (ja) * 2012-06-26 2014-01-16 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体を含有する医薬組成物
AU2013322838B2 (en) 2012-09-25 2018-02-01 F. Hoffmann-La Roche Ag New bicyclic derivatives
WO2015003002A1 (en) 2013-07-03 2015-01-08 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
CR20160496A (es) * 2014-04-04 2017-01-02 X-Rx Inc Inhibidores espirocíclicos sustituidos de la autotaxina
US10093630B2 (en) 2014-05-21 2018-10-09 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
MX2017011997A (es) 2015-03-18 2018-05-28 Abide Therapeutics Inc Carbamatos de piperacina y metodos de preparacion y uso.
AU2016262459A1 (en) 2015-05-11 2017-12-21 H. Lundbeck A/S. Methods of treating inflammation or neuropathic pain
PE20180694A1 (es) 2015-07-31 2018-04-23 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il-carbamato y derivados de 1,1,1-trifluoro-4-hidroxibutan-2-il-carbamato como inhibidores de magl
US10385057B2 (en) 2015-11-20 2019-08-20 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
EP3377060B1 (en) 2015-11-20 2020-08-19 Lundbeck La Jolla Research Center, Inc. Pyrazole derivatives, processes for their preparation and uses thereof
KR102388440B1 (ko) 2016-03-31 2022-04-19 다케다 야쿠힌 고교 가부시키가이샤 헤테로시클릭 화합물
ES2861648T3 (es) 2016-05-12 2021-10-06 Lundbeck La Jolla Research Center Inc Compuestos de espirociclo y procedimientos de fabricación y uso de los mismos
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CA3043610A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Crystalline forms of a magl inhibitor
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
BR112019009992A2 (pt) 2016-11-16 2019-08-27 Abide Therapeutics Inc formulações farmacêuticas
EA201991898A1 (ru) 2017-03-13 2020-02-07 Эбайд Терапьютикс, Инк. Двойные ингибиторы magl и faah
ES2940111T3 (es) 2017-05-23 2023-05-03 H Lundbeck As Inhibidores de MAGL de pirazol
JOP20190267A1 (ar) 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
MA50041A (fr) 2017-08-29 2020-07-08 Lundbeck La Jolla Research Center Inc Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
CR20200088A (es) 2017-08-29 2020-04-08 Lundbeck La Jolla Research Center Inc Compuestos espirocíclicos y sus métodos de preparación y uso
US11434222B2 (en) 2020-11-13 2022-09-06 H. Lundbeck A/S MAGL inhibitors

Similar Documents

Publication Publication Date Title
JP2020500178A5 (OSRAM)
JP2015537008A5 (OSRAM)
JP2020532545A5 (OSRAM)
JP2019104748A5 (OSRAM)
RU2019116512A (ru) Ингибиторы magl
JP2014526533A5 (OSRAM)
JP2018529650A5 (OSRAM)
RU2019115784A (ru) Ингибиторы magl
JP2012092103A5 (OSRAM)
RU2019116514A (ru) Ингибиторы magl
JP2010511721A5 (OSRAM)
JP2020530487A5 (OSRAM)
JP2017522277A5 (OSRAM)
JP2018533593A5 (OSRAM)
JP2016518434A5 (OSRAM)
JP2018510139A5 (OSRAM)
JP2015520140A5 (OSRAM)
JP2014533695A5 (OSRAM)
RU2016150486A (ru) Ингибиторы бета-лактамазы
JP2016518328A5 (OSRAM)
JP2017523225A5 (OSRAM)
RU2017107026A (ru) Ингибиторы идо
JP2016121196A5 (OSRAM)
JP2014511876A5 (OSRAM)
JP2018536634A5 (OSRAM)